Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00142025
Status:
COMPLETED
Last Update Posted:
2009-02-19
First Post:
2005-09-01
Brief Title:
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma
Sponsor:
Centre of Chinese Medicine Georgia
Organization:
Centre of Chinese Medicine Georgia
Study Overview
Official Title:
Randomised Placebo Controlled Double Blind Parallel Group 3-Months Study of Oxcarbazepine Efficacy in Asthma Therapy
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma
Detailed Description:
Effective therapy of asthma still remains quite serious problem According GINA definition asthma is an inflammatory disorder Consequently modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs But asthma also is a paroxysmal disorder many specialists and even some guidelines underline paroxysmal clinical picture of asthma Besides this according to some authors neurogenic inflammation may play important role in asthma mechanism But some other neurogenic inflammatory paroxysmal disorders exist and they are migraine and trigeminal neuralgia Some antiepileptic drugs like carbamazepine and valproate are very effective in therapy of migraine and trigeminal neuralgia - more than in 80 of cases If bronchial asthma also is paroxysmal inflammatory disease like migraine and trigeminal neuralgia it is possible that some antiepileptic drugs also are very effective in asthma therapy
We performed a double-blind placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma Oxcarbazepine is antiepileptic drug of new generation produced by Novartis and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine
Comparison Patients received investigational drug in addition to their usual routine antiasthmatic treatment compared to patients received placebo in addition to their usual routine antiasthmatic treatment
We performed a double-blind placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma Oxcarbazepine is antiepileptic drug of new generation produced by Novartis and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine
Comparison Patients received investigational drug in addition to their usual routine antiasthmatic treatment compared to patients received placebo in addition to their usual routine antiasthmatic treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None